#accessible sick times

In June, the Food and Drug Administration approved the drug Xocova (ensitrelvir) as the very first post-exposure prophylaxis for Sars-CoV-2, and if taken within 72 hours, it could stop a SARS-CoV-2 infection in its tracks. The drug is also being stud

Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, expe